Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate‑to‑Severe Atopic Dermatitis Over a 32‑Week Period: An ECZTRA 3 Post Hoc Analysis

Article full text The above digital features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2022.